// App-Quantinova.ai

P369 : A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Jayastu Senapati

Principal Investigators

  • Nicholas Short

  • Marina Konopleva

  • Farhad Ravandi

  • Nitin Jain

  • Philip A. Thompson

  • Naveen Pemmaraju

  • William G. Wierda

  • Gautam Borthakur

  • Tapan M. Kadia

  • Guillermo Garcia-Manero

  • Musa Yilmaz

  • Jennifer Thankachan

  • Min Zhao

  • Christopher Loiselle

  • Makiel T. Talley

  • Monica I. Kwari

  • Rebecca S. Garris

  • Elias J. Jabbour

Medical Centers

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Luekemia,MD Anderson Cancer Center,Houston,United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

  • Luekemia,MD Anderson Cancer Center,Houston,United States

  • MD Anderson Cancer Center,Houston, TX,Estados Unidos

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Aspartate aminotransferase

  • Alanine transaminase

  • Breakpoint Cluster Region

  • Cytokeratin 20

  • Ph chromosome

  • Creatinine

Drug/Treatment

  • PEG-asparaginase

  • Vincristine

  • Nelarabine

  • Prednisone

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved